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Driven by the efficiency of DNA sequencing and related technologies,
genome- and epigenome-wide association studies have already proven suc-
cessful at producing specific results and general insights about the nature of
genomic regulation. Discovery of expression Quantitative Trait Loci (eQTL),
differentially methylated regions (DMRs), and other genomic and epigenetic
features are proving integral to our understanding of how gene expression and
DNA methylation (DNAm) are controlled throughout the human body and are
changing how genomic and epigenetic data are analyzed in the study of cellu-
lar processes and complex diseases. Epistasis is the interaction among multiple
genetic loci in their effect on gene expression. While epistasis is pervasive in bi-
ological systems and has the potential to account for heritability in traits that re-
main unexplained by the sum of main effects, the computational and statistical
challenges of epistasis detection are daunting. We present the F-test of magni-
tude and concordance (Fomac) - a novel statistic that detects concordant epista-
sis across multiple datasets or co-expressed genes by constraining linear model
parameters to be both significant and consistent. Simulations were carried out
to compare the performance of Fomac to that of comparable methods for de-
tecting single- and multi-trait epistasis, and they showed that Fomac is able to
leverage concordant effects for improved statistical power. Fomac was also ap-
plied to gene expression from the Multiple Tissue Human Expression Resource
(MuTHER) where a genome-wide analysis across 3 tissues identified 2754 ex-
amples of gene-wise Bonferroni-significant concordant epistasis. Epigenome-
wide association studies (EWAS) are providing another angle from which to
view genetic regulation. We performed an EWAS comparing the methylome of
circulating monocytes in patients with and without Charcot foot (a devastating
complication of diabetes.) Increased osteoclast activity has a role in the disease,
and osteoclasts derived from monocytes are particularly well-suited for such a
role. We observed that the methylome of these monocytes was significantly dif-
ferent in patients with and without Charcot foot, and identified specific genes
with aberrant methylation. Together, the studies described in this dissertation
serve the notion that by understanding relationships between and within omics
data, we can both glean useful insights into specific regulatory mechanisms of
the cell and apply patterns to accurately predict biological responses.
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CHAPTER 1
INTRODUCTION
It is like a voyage of discovery into unknown lands, seeking not for
new territory but for new knowledge. It should appeal to those with
a good sense of adventure.
Frederick Sanger, Nobel Banquet, December 10, 1980
1.1 The Omics Revolution
In 1990, the Human Genome Project (HGP) set out to map the 3.4 billion bases
that comprise the human genome. The first genome was published in 2004,
providing researchers with the ability to address new fundamental questions in
genomics[29]. Despite the fact that most of the original reference genome was
pieced together using early-generation DNA sequencing and carried a rich $2.3
billion price tag, the ambition of the HGP stoked a yearning for innovation in
cost, speed, scale, and accuracy of sequencing technologies[87]. By 2014, the cost
of sequencing a human genome had dropped to $1000 and took only a couple
of days[77].
Today, sequencing technologies continue to progress - a genome costing $100
and ready in a few hours is expected to be available within a decade[83] -
and the breadth of applications continues to grow. Pulled along by advances
in DNA sequencing techniques, assays have been established for probing the
transcriptome[131], epigenome, microRNAome[144], and too many more omes
to name[8, 163, 73]. Microarray and more recently next-generation sequenc-
ing techniques have been adapted for high-throughput measurement of gene
expression[141], microRNA[19], and DNA methylation[42]. Mass spectrometry
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and nuclear magnetic resonance have been applied to produce metabolomic[38]
and proteomic[1] data. Each type of data provides a snapshot of certain inter-
related components of the complex regulatory network within cells, making it
possible to interrogate this cellular machinery on a huge scale at both the popu-
lation and single-cell levels[167]. The diverse quality, high production rates, and
raw size of omics data situates genomics squarely in ”big data” territory. Gen-
erally ”big data” refers to datasets large enough that traditional data processing
and analysis methods are insufficient[13]. The torrent of omics data has laid fer-
tile ground for the development of computational and statistical methods de-
signed to glean valuable insights into biology[126, 48], facilitate the transition
from measurement to analysis[21], or feed back to improve the omics technolo-
gies themselves[40]. Substantial effort has already been put into integrating in-
formation across datasets[192], and across[205] and within[142] omes with the
ultimate goal of filling in the gaps in our understanding of cellular regulation.
Still, we face great challenges in acquisition, storage, distribution, and analysis
of omics data. Sequencing technologies continue to improve and the demand
for their services are growing - estimates range from 100 million to 2 billion
human genomes being sequenced by 2025[213] - and that’s only genomic data.
The multitude of omics data are derived from different but biologically related
layers of cellular regulation, meaning that there will be a greater demand to
integrate information from multiple datasets[108]. Time-series measurements,
measurements over multiple tissues, and biological replicates among other de-
signs further increase the dimensionality of this already heterogeneous mass of
data.
Uncovering the regulatory processes responsible for cellular and organis-
mal function is a fundamental goal in biology[16]. These insights underpin
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disease prevention and treatment of all types[116]. The richness of omics
data has already allowed us to address a broad range of questions, from ba-
sic science inquisitions like when early humans left Africa[197] to mechanisms
of post-transcriptional regulation in Huntington’s disease[88] and Parkinson’s
disease[89], and translational medicine advances like targeted therapies for
cancer[71, 146]. Genomic data alone can be used to test phylogenetic hypothe-
ses of agricultural significance[201]. Genomic data can be paired with readily
available clinical data to identify causal/risk loci in complex phenotypes[228].
Transcriptomic (gene expression) data can be paired with genomic data to
identify genetic markers that are highly predictive of gene expression[171].
Metabolomic data can be integrated with transcriptomic data to identify gene-
to-metabolite networks[84]. Each of these approaches involves identifying re-
lationships within and/or among omics datasets, and each interaction type can
shed light on a slightly different part of cellular regulation. This dissertation will
focus on (1) associations between and within the genome and transcriptome, (2)
interactions between the methylome and clinical phenotypes, and touch on in-
teractions between the methylome and transcriptome.
1.2 Genome-Wide Association Studies
As DNA sequencing throughput increased, it became possible to sequence thou-
sands of genetic markers, including single nucleotide polymorphisms (SNPs) in
a short period of time for many samples[151]. Genome-wide association stud-
ies emerged as a means to comprehensively test the genome for SNPs in close
proximity to a genetic locus causal to qualitative or quantitative phenotypes
(traits)[228]. Since it is rare for traits to feed back to alter the genetic locus it-
3
self, we assume the primary direction of regulation is that the locus causes dis-
ease/disease risk. We often refer to such an occurrence as a genetic effect or ge-
nomic association. An advantage of GWAS over previous association studies is
that it represents an unbiased and comprehensive option that can be performed
without a priori knowledge of causal genes[67]. Thousands of GWAS studies
have been published[117] and have identified numerous genetic loci associated
with complex traits like BMI[212], as well as risk loci and therapeutic targets for
complex (non-Mendelian) diseases like coronary artery disease[222, 125, 206].
GWAS are allowing us to understand contributions to complex disease from
SNPs across the genome[140]. Still, relatively little is known about the genes
and genetic variants influencing susceptibility to common human diseases[5].
The majority of SNPs identified by GWAS are located in non-coding regions
of the genome[143], which suggests a role in transcriptional regulation. Trait-
associated SNPs are also more likely to influence the expression of one or more
genes[169] than non-trait-associated SNPs, suggesting that there is a link be-
tween the genetic regulation of gene expression and that of complex traits[30].
1.2.1 Expression Quantitative Trait Loci
As DNA microarrays[200] and whole transcriptome shotgun sequencing (RNA-
Seq)[231] technologies were developed, it became possible to test millions of ge-
nomic markers for association with tens of thousands of gene expression levels.
These associations are called expression quantitative trait loci (eQTL) (Figure
1.1), and studying them is particularly insightful since intermediate phenotypes
like gene expression are often separated from genetic influence by fewer regu-
latory steps compared to complex traits[68]. Therefore, a genetic effect should
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be more easily detectable at the gene expression level than at the level of any
complex (non-Mendelian) disease for example[255]. Given that GWAS have
already identified many genomic loci involved in disease/disease risk, and dif-
ferential expression analyses have long investigated the transcriptome’s role in
disease[6], understanding how a genomic locus regulates gene expression can
help reveal mechanisms involved in a phenotype that is also impacted by that
same genetic locus. In other words, eQTL can help us probe how the genome
impacts disease through transcriptional regulation and other mechanisms.
Figure 1.1: Types of eQTL Main Effects. Top row: scatterplots, each
showing gene expression across the three genotype classes.
Bottom row: genotype-phenotype (GP) maps visualizing the
mean gene expression using color for each genotype class with
blue indicating low expression, black indicating global mean
expression, and yellow indicating high expression. An eQTL
exists when the mean expression of at least one genotype class
is different than the global mean (center and right columns),
but no eQTL exists when all genotype classes have the same
mean gene expression (left column). Main effects are decom-
posed into orthogonal additive (center) and dominance (right)
effects.
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Since genetic loci can take on one of three values in genetic variants, they
can be represented as a 3-category variable or as 2 orthogonal ordinal ”dummy”
variables. In Figure 1.1, the center and right plots contain additive and domi-
nance main effects, respectively. Main effect describes a statistical association
between a single SNP and the trait. Decomposing the 3-category genotype vari-
able into 2 ”dummy” variables that capture these additive and dominance ef-
fects creates a suitable design for linear regression, which models gene expres-
sion as a linear combination of one or both of these ”dummy” variables[69].
PLINK[184], a widely distributed software for efficient genomic computations,
defines the additive coding of the gth genotype as
Gg,a =

0 if Gg = AA
1 if Gg = Aa
2 if Gg = aa
such that the additive coding captures how many reference alleles an individual
has. Still another additive coding for the gth genotype is
Gg,a =

−1 if Gg = AA
0 if Gg = Aa
1 if Gg = aa
which will capture the same main effect as PLINK’s coding, but will diverge
from PLINK’s outcome when genotype interactions are considered. Still, this
ordinal coding will not be sensitive to dominance effects where the mean ex-
pression of heterozygotes is greater than that of either homozygote. Therefore,
dominance codings are often defined for the gth genotype as
6
Gg,d =

0 if Gg = AA
1 if Gg = Aa
0 if Gg = aa
or
Gg,d =

−1 if Gg = AA
1 if Gg = Aa
−1 if Gg = aa
Analagously to the additive case, both of these dominance codings will cap-
ture the same main effect but will diverge when genotype interactions are con-
sidered. Other dominance codings with identical properties that capture differ-
ent scalings of the same effect exist in the literature(citation).
Most current fast implementations of genome-wide eQTL analyses either
use this linear regression approach or a derivative of analysis of variance
(ANOVA) to calculate p-values for all of the billions of possible genotype-gene
expression combinations[65].
What have we learned from eQTL studies?
Many eQTL have been identified in plants[234, 41], mice[112], humans[226,
122, 180, 166, 10, 247, 26, 214, 50], and have also been specifically validated in
yeast[18]. eQTL where the locus is proximal to the gene it regulates are called
cis-eQTL, otherwise they are called trans-eQTL. Although cis-eQTL appear to
be more abundant[66] and to have larger effect sizes[176] than trans-eQTL, cis-
eQTL are also preferentially advantaged in both of these areas due to many
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studies limiting the scope of their search to cis-genomic regions in order to limit
multiple test correction. Cis-eQTL also appear to replicate more readily across
independent datasets than trans-eQTL[190], suggesting that trans-eQTL may
be more sensitive to experimental conditions like tissue heterogeneity[183] than
cis-eQTL.
There is evidence of connections between loci involved in disease and eQTL:
one study reported that 23.1% of catalogued GWAS hits for adult-onset neuro-
logical disorders showed up as a cis-eQTL signal in their analysis of various
brain tissues[190]. For this reason, eQTL and GWAS have been integrated to
help understand complex disease [154, 129, 171]. Systems genetics, which seeks
a broad view of the molecular basis of complex traits, incorporates eQTL re-
sults with those from other layers of regulation to infer directional expression
networks[27]. Studies involving eQTL show enrichment for eQTL in methy-
lated DNA regions[12], regions of open chromatin[62], and transcription factor
binding sites[37], which all serve to verify that results from eQTL studies are
meaningful in the context of the integrative biological picture that we’re trying
to uncover.
At least 50 eQTL datasets are now available, ranging from consortia of hun-
dreds of samples across at least 40 tissues[134] to single studies with thousands
of samples of genome-wide genotypes and gene expression[239]. In the abun-
dance of eQTL datasets (those with thousands of genomic loci and expression
measurements for thousands of genes), numerous methods have emerged to
faciliate the discovery of expression-impacting SNPs on a new whole-genome
whole-transcriptome scale[94, 215].
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Table 1.1: eQTL Datasets and Cell Lines Small sampling of available
eQTL datasets for different tissues, sample sizes, and genotyp-
ing and gene-expression measurement platforms
Challenges of eQTL Studies
Heritability is the proportion of phenotypic variation that is due to genetic vari-
ation, and is a central question in the modeling and prediction of complex
phenotypes[238]. Most heritability in gene expression is not explained by de-
tectable eQTLs[18] or epigenetic inheritance[183], suggesting that gene expres-
sion is influenced by many genetic loci of small effect, including many trans-
eQTL.
As most eQTL studies transitioned to true genome-wide searches including
both cis- and trans-loci, the challenges of working with ”big data” took hold[95].
Genome-wide studies involving hundreds of thousands of SNPs and thousands
of genes are understood to be a case of ”large p, small n”, which refers to when
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the number of features p greatly exceeds the number of samples n[23]. Many
computational[205] and statistical[185] approaches have popped up to deal with
the difficulties of looking for genomic effects in such a huge search space[2].
1.2.2 Epistasis
While many eQTL involving a single locus impacting gene expression (referred
to as marginal/additive effects) have been identified in a variety of biological
systems [180, 156, 75], a large portion of heritability remains unexplained by
these additive effects[140, 227]. It is clear that focusing on main effects is likely
an oversimplification of the underlying biology since phenotypes are often af-
fected by multiple genes in complex ways[43, 56].
Epistasis describes when the effect of a genetic locus on a trait is modulated
by other genetic loci - a concept central to genetic regulation[178] - and known to
play a role in molecular evolution[17], protein evolution[145], and the evolution
of transcriptional networks[211]. The term has its roots in the early 20th century
when Bateson described epistasis as an allelic effect at one locus being masked
by the effect of another allele at a different locus[9] - a biological phenomenon
and a well-developed area of research[7, 177, 74]. A decade later, Fisher defined
epistasis as any statistical deviation from the sum of strictly additive genetic
effects of two loci in their impact on a trait[55].
Despite the common name and similar sounding descriptions, the two def-
initions are not equivalent. Bateson’s is a biological definition applying at the
level of the individual whereas Fisher’s is a statistical definition applied at the
population level. We do know that it is possible for biological epistasis to be
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present in the absence of statistical epistasis[159], but the degree to which sta-
tistical evidence of epistasis at the population level constitutes evidence of bio-
logical epistasis is still an active area of debate[54, 32, 160].
Statistical epistasis can be visualized through a contingency table that shows
the mean phenotype value for all combinations of g genotypes, each of which
can take on 3 values in diploid cells. The table therefore has g dimensions and
3 categories per dimension for a total of 3g entries (2-way epistasis example in
Figure 1.2. A genetic effect is therefore represented by a difference in the mean
phenotype value among any of the 3g genotype classes. Such an effect will be a
combination of main effects and epistatic effects, and can be deconstructed into
features that capture either purely main effects or purely epistatic effects (Figure
1.2) with the proper parameterization[102]. If distinguishing main effects from
epistatic effects is not a priority, a general genetic effect can be tested for by
employing an ANOVA on the 3g groups[80].
From early on, accounting for epistatic interactions improved linkage
studies in inflammatory bowel disease[25], type 2 diabetes[33], and other
diseases[193]. Accounting for genetic interactions has already improved mod-
eling of quantitative traits in yeast[57], and there is compelling evidence that
epistasis plays a role in Alzheimer’s disease[44, 20]. Epistasis has been utilized
to successfully improve models of genetic regulation of clinical disease[148] and
intermediate traits like gene expression (eQTL epistasis). Most quantatitive trait
analyses in animal[103, 96, 207] and plant[104] models suggest that statistical
epistasis is widespread.
While epistasis can be detected in linkage or association analyses, and in
qualitative or quantitative traits, this discussion specifically deals with eQTL
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Figure 1.2: Genotype-phenotype (GP) map showing color-coded mean
expression values for each of the 9 genotype classes defined
by the joint states of two genotypes (top right). Lack of main
effects (below and to the left of GP map) means that the pattern
visible in the GP map is due to epistasis.
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epistasis which is when the effect of a genetic locus on gene expression is mod-
ulated by other genetic loci[123].
Mathematical Formulation
Fisher’s work gave rise to the mathematical definition of epistasis most com-
monly used by quantitative genomicists today - deviation from additivity (main
effects) in the effects of multiple loci on a trait. As a baseline for this additivity,
a set of features spanning all possible types of main effects is first defined. Con-
sider two genetic loci G1 and G2 each of which can take on three possible values
in a diploid organism. The loci are each transformed into two dummy variables
which encode the same information as the original categorical coding. Define
the additive coding of the gth genotype as
Gg,a =

−1 if Gg = AA
0 if Gg = Aa
1 if Gg = aa
and the dominant coding of the gth genotype as
Gg,d =

−0.5 if Gg = AA
1 if Gg = Aa
−0.5 if Gg = aa
Consider a quantitative phenotype Y that we are interested in testing for
association with these traits jointly. A full two-locus linear regression for main
effects has the form
Y = β0 + β1,aG1,a + β2,aG2,a + β1,dG1,d + β2,dG2,d + 
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where β represents the strength of a genetic effect and  is error. A full two-
locus linear regression accounting for epistasis has the form
Y = β0 + β1,aG1,a + β2,aG2,a + β1,dG1,d + β2,dG2,d + βa,aG1,aG2,a
+βa,dG1,aG2,d + βd,aG1,dG2,a + βd,dG1,dG2,d + 
If dummy coding and model parameterization is performed properly, a set
of genomic features can be generated such that all epistatic features are orthog-
onal to all main effect features in the asymptotic limit for certain distributions
of alleles[102]. In this scenario, epistatic features represent true epistasis (Fig-
ure 1.2) - independent of main effects from the involved genotypes. However,
in many realistic settings, the distribution of samples dictates that epistatic fea-
tures may not be perfectly orthogonal. This means that main effects may be
detected as epistasis in these settings[35].
By fitting these two linear regressions and treating the first and second mod-
els as null and alternative, respectively, we can test for the presence of epistasis.
A likelihood ratio test is constructed under the null hypothesis that the two
models explain Y equally well. If the epistasis model explains Y better than the
main effect model, epistasis is present and the likelihood ratio test will allow
rejection of the null hypothesis. Alternatively a Wald test can be performed on
epistasis parameters of the alternative model[72].
Challenges of Epistasis Detection
The sequencing technology enabling comprehensive eQTL studies has made
the ”large p, small n” problem relevant to genome-wide eQTL studies - but
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Figure 1.3: Examples of Epistatic Effects (Using the genotype codings de-
fined just above, epistasis effects were generated and visual-
ized using GP maps)
the same problem is exacerbated due to the combinatorial quality of epistasis
(interaction) testing. Detecting interactions among variables is a well-known
challenge in statistics and data mining[59]. If an eQTL dataset contains 1 mil-
lion SNPs, it contains over 100 billion possible 2-way combinations of SNPS
and over 100 quadrillion possible 3-way combinations. Such a combinatorial
explosion presents challenges both computationally and statistically. Computa-
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tionally, more tests means computation quickly becomes prohibitive as epistasis
order (interaction order) is increased. Statistically, the problem comes down to
reduced statistical power due to heavy multiple test corrections and epistasis re-
quiring more heavily parameterized models. In order to balance false positive
and false negative rates, multiple test correction must be employed; more tests
overall means a heavier multiple test correction meaning that an effect must be
detected more strongly in order to be identified. Since epistatic effects can take
more forms than main effects, this necessitates either parameterizing a model
more heavily or submitting a simple model to even more statistical tests[81].
The statistical challenges can be summarized in an analogy to needles (epis-
tasis among loci) in a haystack (all possible interactions where epistasis could
exist)[194]. Detection of epistasis encounters two primary difficulties: (1) Can
one look for needles in the correct part of the haystack? (the ”search” module
of epistasis detection), and (2) If presented with a needle, can one distinguish it
from hay? (the ”identify” module of epistasis detection). Epistasis detection can
therefore be thought about as a problem involving at least two modules, first for
searching the genome broadly for epistasis and second for identifying the loci
involved and the form of epistasis.
Approaches to Epistasis Detection
Many approaches have been developed to address the statistical challenges of
epistasis detection. These can be labeled according to which module of epistasis
detection they primarily address. Methods addressing the ”Identify” module
are designed to look at specific candidate associations, without consideration of
the fact that the candidate is one in a sea of billions of potential associations[252].
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These methods almost always utilize some sort of filtering in order to reduce the
multiple test burden, but filtering is not their focus. An example is the additive-
by-additive linear regression parameter that PLINK uses to test for a limited set
of epistatic effects[22]. Methods classified as ”Search/Identify” acknowledge
the enormous size of the genetic feature space and are therefore designed to
address both the ”Search” and ”Identify” modules in an inseparable manner
using constructs like random forest[244] and multidimensional reduction[195].
”Search-Then-Identify” methods address both modules of epistasis detection
but in a modular, separable way with an equal emphasis on the two modules.
These methods usually filter the total possible number of tests down by either
imposing knowledge derived from biology[82] or the data itself[149].
Another primary consideration is that most methods for detecting epista-
sis may not work for eQTL because they are designed to handle case/control
traits and do not generalize to quantitative traits either in design or software
implementation[240, 218].
Many methods have also been developed to address the substantial compu-
tational challenges of epistasis detection: FastEpistasis[203], FastANOVA[251],
and EpiSNP[136] are just a few of the numerous examples.
Epistasis and Pleiotropy
Interactions among DNA, RNA, proteins, and other cellular constituents form
the connections of highly complex regulatory networks. One feature of this
complexity presents as functional and genetic redundancy, which are well-
documented in biology [110]. For example, in C. elegans parallel and redun-
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dant genetic pathways regulate dauer formation [179]. This regulation involves
two groups of genes, regulated by the same pheromone, which positively reg-
ulate dauer formation through a functionally identical but physically separate
pathway. In general, a set of genetic features (main and/or epistatic) that reg-
ulate expression of a particular gene can regulate at least one other gene - this
is known as pleiotropy. More generally, pleiotropy involves mapping one com-
ponent of the genome to multiple traits[172]. The existence of functional redun-
dancy dictates that this regulation could be fully or partially redundant. In other
words, a set of genetic features could regulate multiple genes in a similar man-
ner, which would produce correlations among the genes and among the genetic
models containing those genetic features. In its current conception, pleiotropy
is categorized into two main forms: vertical and horizontal (Figure 1.4). Vertical
pleiotropy describes when a locus has an effect on more than one phenotype in
a causal chain. As such, vertical pleiotropy represents a combination of genetic
and physiological effects. Horizontal pleiotropy describes when a locus affects
more than one phenotype independently[223]. Among instances of horizontal
pleiotropy is a specific type of genetic regulation - parsimonious pleiotropy[85] -
which may present statistically when a locus has the same type of genetic effect
on multiple phenotypes.
Pleiotropy and Epistasis do have a history of being detected independently:
canonical correlation analysis (CCA) has been used to test the overall associa-
tion between a genotype and multiple phenotypes[53] - and jointly: information
from multiple phenotypes is used to constrain potential models of epistasis and
to produce genetic networks that influence these quantitative traits [224].
18
Figure 1.4: Horizontal and Vertical Pleiotropy With and Without Epista-
sis. In horizontal pleiotropy a genetic variant (G) directly reg-
ulates multiple genes (P1 & P2). In vertical pleiotropy G regu-
lates P1 directly and is associated with P2 by way of P1. Mul-
tiple genetic variants can also exhibit pleiotropy, as shown in
the bottom two illustrations. In horizontal epistatic pleiotropy
multiple genetic variants (G1 & G2) directly regulate P1 and
P2 in a non-additive manner. In vertical epistatic pleiotropy
G1 and G2 regulate P1 directly and are associated in a non-
additive manner with P2 by way of P1.
Replication
Despite success of eQTL studies and the prevalence of biological and statistical
epistasis in complex traits[159], failure to reproduce early epistasis analysis re-
sults has placed renewed emphasis on replication in eQTL studies with[80] and
without[109, 253] epistasis. Evidence is scarce on whether this lack of replica-
tion is due to spurious results or condition-specific genetic effects. Still, replica-
tion is a minimum standard for scientific results. Failure to replicate association
study results hurts their generalizability and renders them less interpretable
and less actionable[153]. Assessing replication can demonstrate that the identi-
fied effect is present in multiple independent datasets, reducing the chance that
a dataset-specific artefact has produced a false positive. Biological differences
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among datasets such as samples derived from different populations, different
tissues, general batch effects across datasets, etc. serve to improve the potential
for generalizability of any result produced that agrees across datasets.
There is also room for interpretation as to what is meant by ”replication”[86].
One person could say that replication has occurred if an epistatic effect between
a set of genotypes and a phenotype exists in multiple datasets. However, epis-
tasis can take multiple forms - many of which could have different implications
for an underlying mechanism. If epistatic effects of different forms were to show
up in replicate datasets, this would indicate a higher chance of either a false pos-
itive or the datasets differing across some condition of importance. Therefore,
it may be prudent to constrain the form of any epistatic effects to be consis-
tent/concordant across conditions in order to demonstrate replication. Concor-
dant epistasis exists when multiple quantitative traits contain similar/identical
epistatic effects for a given set of genetic loci. In Figure 1.5, the marginal and
two-way epistasis patterns are displayed for three different quantitative traits
(may be different genes within the same dataset or the same gene across differ-
ent datasets). Since marginal effects are absent but identical epistasis patterns
are present, this represents epistasis that is concordant across conditions. These
quantitative traits may represent expression measurements of different genes,
or expression measurements of the same gene under different conditions (pop-
ulations, tissues, etc).
Meta-analysis approaches can be performed to assess replication, but differ-
ing minor allele frequencies and other concerns between populations can make
it impossible to replicate an effect that might have otherwise shown up in con-
ditions of consistent minor allele frequencies across datasets. Hemani et al.[80]
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Figure 1.5: Concordant and non-concordant epistatic effects
found epistatic effects that replicated in 2 independent datasets. Their discovery
power was limited to that of the original dataset since only SNPs identified as
being globally significant in the original dataset were available to be validated
in replication. Still, it is encouraging that in their study 22 of 30 interactions that
were significant in all three datasets were concordant in effect.
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Epistasis in Multiple Traits
The development of multivariate epistasis methods has been motivated by the
need for methods to utilize/assess replication in eQTL epistasis studies as well
as the plausibility of pleiotropy arising from the joint effect of two genetic loci.
Multiple traits have also been incorporated into epistasis and eQTL mapping in
order to find pleiotropy among genes [249, 224] or effects that replicate across
datasets[113]. Considering multiple traits jointly has the potential to improve
statistical power while providing useful information on the dependence struc-
ture of traits as it relates to genomic associations. Despite the numerous meth-
ods designed to detect 2-way and higher order epistasis[233] or genomic as-
sociations across multiple traits[63], few methods exist to detect epistasis across
multiple traits. Results from testing for epistasis in individual traits can be meta-
analyzed[58] or p-values can be combined across traits using Fisher’s combined
probability test or similar method[99]. Multivariate multiple regression also
makes sense for this type of analysis because it can incorporate multiple traits
into a model parameterized by multiple epistatic effects[161]. CAPE aims to
detect epistasis by integrating information from multiple phenotypes that are
influenced concordantly by genomic interactions[224]. MFRG tests for interac-
tion between two genes jointly in multiple quantitative traits[249]. Zhang de-
veloped a Bayesian method for identifying epistasis and pleiotropy by treating
co-expressed genes as a module[250]. Table 1 provides a list of methods for
detecting epistasis in single and multiple traits.
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1.3 Epigenome-Wide Association Studies
1.3.1 DNA Methylation
Advances in DNA sequencing have also transformed the study of epigenetics
by enabling the measurement of features like chromatin interactions[121], hi-
stone modifications[173], and DNA methylation[28] using next generation se-
quencing technologies. Epigenetics is a broad term, encompassing many mi-
totically heritable elements which serve to modulate genetic function, and has
therefore also been proposed to contribute to the missing heritability viewed
in common human diseases[209, 220]. Epigenetics is known to play a sig-
nificant role in development, cancer, cell differentiation, and development of
cancer through aberrant cell differentiation[106]. Epigenetic alterations com-
monly alter chromatin accessibility, which in turn alters interactions between
the DNA and regulatory elements[216]. One form of epigenetic alteration is
DNA methylation (DNAm), which refers to methylation of the 5‘ position of
a cytosine nucleotide[52]. DNAm is a key molecular mechanism in embry-
onic development, transcription, chromatin structure, X chromosome inacti-
vation, genomic imprinting and chromosome stability[128, 196, 191, 45, 210].
In humans, the majority of DNAm in humans happens to CpG dinucleotide
pairs[256]. CpGs have a statistically underrepresented[237, 60] and patterned
distribution throughout the mammalian genome - an early indicator of the in-
sights they would produce[208]. Epigenetic features involving CpGs include
”CpG islands” (CGIs), which are regions of CpG site enrichment near promot-
ers that generally remain unmethylated across conditions[36]. Approximately
60% of human genes are associated with CGIs[105]. Despite the many elements
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present in the epigenome - known and unknown - numerous studies claim
to have performed epigenome-wide association studies (EWAS) by looking at
DNA methylation[188], presumably judging the methylome a sufficient proxy
for the entire epigenome.
1.3.2 Role in Disease
Methylation variable position (MVP) is the methylome equivalent of a SNP in
the genome, and displays differential methylation[189]. Differentially methy-
lated regions (DMRs) consist of nearby adjacent CpG sites that are usually less
than 1kb in length and have variable methylation between samples[165]. Both
MVPs and DMRs represent epigenetic variation that could be associated with
a condition like disease state, cell type, etc. via upstream and/or downstream
regulation.
CpG islands have been observed to undergo aberrant hypermethylation
during extended proliferation in vitro[150], suggesting that methylation may
have a role to play in cancer treatment[11]. DNAm also plays a role in silenc-
ing repetitive DNA elements[51], and the loss of methylation of repetitive ele-
ments is an epigenetic hallmark of cancer[130]. Genome-wide loss of DNAm is
also an early and frequent occurrence in cancer, and is associated with sever-
ity of cancer in many different tumour types[235]. Tissue- and cancer-specific
DMRs appear more often in regions up to 2kb away from CGIs called ”CpG
island shores”, and have been strongly related to both gene expression and
disease[101], suggesting more complex patterns of functional CpG methylation
distribution throughout the genome.
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The epigenome appears to be highly tissue-specific, which has placed an
emphasis on analysis accounting for cell-type heterogeneity[147, 61] and devel-
opment of cell-type specific assays[91]. This tissue-specificity may be an advan-
tage for clinical application of DNA methylation data. Biomarkers for disease
or disease risk can be detected in epigenetic screens of cells from readily avail-
able tissue such as blood. Unlike the genome, the methylome can be greatly
impacted by disease. Disease-distinguishing epigenetic elements (that may also
be tissue-specific) can thus indicate the presence or absence of particular dis-
eases (biomarker)[133].
1.3.3 Performing EWAS
An epigenome-wide association study (EWAS) is the methylome equivalent of
the GWAS. In EWAS, millions of CpG methylation sites or thousands of DMRs
thoughout the methylome are tested for association with a trait such as disease
or adiposity[230]. Like GWAS, EWAS are a means to comprehensively search
for associations between genomic state and a trait. However, EWAS differ from
GWAS in two primary ways. First, unlike the genetic variants, DNAm is ex-
tremely sensitive to cell type and therefore tissue type, so potential cell-type
hetergeneity must be accounted for in the assay and/or analysis[257]. Second,
epigenetic changes may contribute to a trait and/or occur downstream of the
trait[182]. While this causal ambiguity may contribute positively to the utility
of DNAm as a diagnostic or prognostic biomarker, it makes inferring regula-
tory causation more difficult compared to GWAS. Still, such inferences can be
made with careful study designs or by leveraging other omics data. An EWAS
for type I diabetes measured DNAm before and after diagnosis in order to ex-
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plore disease aetiology[187]. More recently, results from EWAS and methylation
quantitative trait loci (where SNPs affect DNAm) analyses were integrated to
establish multiple lines of evidence that increased BMI was most likely causing
increased DNAm levels rather than resulting from it[39].
Differential expression and differential methylation analyses have been in-
tegrated to identify instances of reduced methylation at gene promoters and
increased gene expression, or vice versa[98]. A joint methylation and gene ex-
pression analysis pipeline that executes the same general procedure is show in
Figure A.1.
1.4 Overview of Dissertation
My work has involved developing computational and statistical techniques for
probing large groups of genetic variants, gene expression profiles, DNA methy-
lation profiles, and clinical data for evidence of interactions within or across
these omics readouts. I developed a novel asymptotically correct statistic (Fo-
mac) for detecting low and high order statistical epistasis (interactions among
genomic regions) in quantitative trait locus studies. Then, I probed genome-
wide DNA methylation to find associations between methylated genomic re-
gions, the whole methylome, and the disease Charcot foot.
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1.4.1 Chapter 2 - Fomac (F -test of Magnitude and Concor-
dance)
Chapter 2 focuses on Fomac, which is a novel statistic flexible enough to test for
concordant epistasis involving an arbitrary number of traits and genetic loci. Fo-
mac is designed to detect instances where the epistatic parameters across several
traits are both significant and in agreement, like in the top of Figure 1.5. Justifi-
cations for pursuing concordant epistasis, theoretical underpinnings of Fomac,
and application to simulated and real biological data will be covered.
1.4.2 Chapter 3 - Connections Between CpG Methylation and
Charcot Foot
Chapter 3 covers an EWAS study that was performed using isolated monocytes
from 54 patients with type II diabetes and varying levels of the disease Charcot
foot to discover DNAm correlates of the disease. Differential methylation be-
tween disease and control was assessed in three ways, each demonstrating that
the methylome was significantly different between patients with and without
Charcot foot. Pathway analysis on differentially methylated genes unveiled a
possible role of circulating monocytes in the pathogenesis of Charcot foot.
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CHAPTER 2
A NOVEL ASYMPTOTICALLY CORRECT STATISTIC FOR DETECTING
PAIRWISE AND HIGHER ORDER CONCORDANT EPISTASIS ACROSS
MULTIPLE QUANTITATIVE TRAITS
Epistasis describes the interaction among multiple genetic loci in their asso-
ciation with a trait such as gene expression (eQTL epistasis), and is emerging as
a potential solution to the problem of missing heritability and as a tool for un-
covering the structure of genetic pathways. Despite the abundance of methods
designed to address the computational burden and reduced statistical power
of genome-wide testing for epistasis, detecting epistasis remains difficult and
replication of epistatic effects remains rare. The need for flexible meta-analyses
also grows with the demands of big data only set to expand in the near fu-
ture. We propose a novel method Fomac: F-test of magnitude and concordance
which jointly tests multivariate linear regression epistasis parameters for sig-
nificance and consistency to identify concordant epistatic effects across traits.
By specifically constraining the form of epistatic effects to be consistent across
traits, we gain increased statistical power to identify these effects in high noise
regimes. Fomac can be applied to sets of coexpressed genes within one sample
(dataset) to discover pleiotropy, or applied across multiple samples with simi-
lar characteristics to find examples where epistatic effects are consistent across
conditions (replication). We demonstrate in simulations capturing the effects of
different sample sizes, epistasis orders, and number of traits on relative method
performance that Fomac outperforms several comparable methods for detect-
ing epistasis. The Fomac framework was applied across 3 genome-wide geno-
type and gene expression datasets of 618 individuals from the TwinsUK registry,
and demonstrated a well-calibrated test statistic and several examples of tissue-
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concordant epistasis. The fomac test-statistic is also compatible with many of
the top frameworks already available, meaning it can act as a standalone or
complementary tool for detecting concordant eQTL epistasis.
2.1 Introduction
Expression quantitative trait loci (eQTL) are instances where a genetic locus
is associated with gene expression. While eQTL exhibiting main effects have
been central to our understanding of the regulatory architecture of complex
traits[190], it is clear that focusing only on main effects is likely an oversimpli-
fication of the underlying biology since most phenotypes are affected by mul-
tiple genes[43] in ways that are not strictly independent[56]. Indeed, a large
portion of heritability in gene expression remains unexplained by these main
effects[140]. Epistasis can be viewed on a population level as any statistical de-
viation from the sum of strictly additive genetic effects of two loci in their effects
on a trait[55]. Epistasis has been proposed as a solution to the problem of miss-
ing heritability[140, 138, 47], as well as a tool for elucidating the structure of
genetic pathways[111]. Epistasis is pervasive on both the organismal[204] and
population[158, 223] levels. Still, the combinatorial explosion of considering
genotypes combinations has caused greatly increased computational demands
and reduced statistical power in epistasis studies[97]. The ever-growing nature
of genomic data suggests that sample sizes will grow in the coming years - the
challenge will be designing methods for leveraging the growing sample sizes
of these data while remaining robust to high dimensional and heterogeneous
data[93].
Many approaches have been applied to detect epistasis in gene expression
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and complex traits, varying from parametric methods like linear regression[181]
and bayesian inference[250, 241] to nonparametric methods like decision
trees[244] and other method types[149]. Parametric methods have the advan-
tage of being able to explicitly test for specific epistasis patterns while nonpara-
metric methods have the flexibility to capture a wide range of effects[92]. The
linear regression framework serves as the basis for a great many methods which
have adapted the framework with different genotype codings and choices of
parameters to include in the model[184, 54, 242]. Genotype coding refers to
the choice made when transforming a genotype variable from categorical to or-
dinal - several different codings are represented in the literature, each captur-
ing slightly different epistatic effects[161, 243, 164]. There is also disagreement
about whether to use a single epistasis parameter or more heavily parameter-
ized full epistasis model[31].
With the renewed emphasis on replication of eQTL results[100], studies
have also found that epistatic effects can replicate[232] and be concordant[80]
across multiple datasets. Assessing replication can demonstrate that the iden-
tified effect is present in multiple independent datasets, reducing the chance
that a dataset-specific artefact has produced a false positive. Meta-analysis ap-
proaches can be performed, but differing minor allele frequencies and other
concerns between populations can make it impossible to replicate an effect that
might have otherwise shown up in conditions of consistent minor allele fre-
quencies across datasets. Hemani et al.[80] found epistatic effects that replicated
in 2 independent datasets. Further constraining the search to concordant effects
has the potential to increase statistical power and identifies epistatic effects that
are both replicable and robust to setting, which improves the chances that effects
are generalizable and interpretable.
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In this study we present Fomac, a novel statistic that detects concordant epis-
tasis by leveraging the idea that when multiple traits are impacted by similar
epistatic effects, the estimated parameters of models capturing these effects will
be similar and will cluster together in parameter space. This asymptotically cor-
rect statistic makes use of the known null distribution of linear regression pa-
rameter estimates in order to calculate an f-statistic jointly evaluating the degree
to which (1) the epistasis models are different than the null model (i.e. epistatic
effects exist), and (2) the epistasis models are identical to each other (i.e. the
epistatic effects are concordant). By requiring effects to be concordant across
traits, we are able to detect concordant epistasis in higher noise conditions than
comparable single- and multi-trait methods. The FOMAC test statistic can be
applied to the same trait across different datasets to leverage replicating effects
for epistasis discovery, or applied across different traits like coexpressed genes
within a single dataset to discover pleiotropy.
Simulations were carried out to compare the performance of Fomac to that
of comparable methods for detecting single- and multi-trait epistasis. We show
that Fomac identifies more examples of concordant epistasis than the other
methods in high-noise regimes and under 6 different simulation parameter set-
tings. Fomac was also applied to gene expression from the Multiple Tissue
Human Expression Resource (MuTHER)[168] where a genome-wide analysis
across 3 tissues identified 2754 examples of gene-wise Bonferroni-significant
concordant epistasis.
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2.2 Methods
In its most general form the Fomac framework (Figure 2.1) accepts as input r
datasets, each containing 1 trait and g genotype variables, and tests for g-way
epistasis that is concordant across all datasets. However, in this general form
notation is unwieldy, computation takes longer, and variations in allelic distri-
butions between different populations reduce statistical power to detect genetic
effects[157]. Therefore, it makes sense to match samples if possible. If sam-
ples are matched across all r traits - as they might be in analyses of time-series
data, cross-tissue data, or pleiotropy analyses within a single dataset - param-
eter estimates correspond to those produced by multivariate regression, which
involves more streamlined notation and computation compared to the case of
unmatched samples. For both notational simplicity, computational efficiency,
and to maximize statistical power, Fomac will be discussed here and applied to
simulated and real data in settings where samples are matched across traits (fig
2). However, Fomac has the theoretical flexibility to handle multiple traits of
different sample sizes and/or entirely different samples.
2.2.1 The Fomac Framework
Fomac starts with r traits and g genotype variables. The multivariate multiple
regression model has the form
Y = Xβ + E (2.1)
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Figure 2.1: The Fomac Framework. Top Left: Fomac accepts a set of r
traits and g genotypes. Top Right: Fomac can leverage highly
parameterized models, so genotype variables can be readily
transformed into several epistasis features. Bottom Left: Mul-
tivariate linear regression produces parameter estimates and
estimates for distributions of these parameter estimates. Bot-
tom Right: Fomac operates on these parameters to assess how
concordant and significant epistatic effects are across traits.
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where Y and is a known n × r matrix of traits, X is a known n × p matrix of p
epistasis features, β is an unknown p× r matrix of p epistasis parameters across
r traits, and E is a n× r random matrix with rows independently distributed as
N
(
0,Σ
)
. In the case of epistasis detection X will contain features capturing in-
teractions among the g genotype variables. Including intercept and main effect
terms does not disrupt this procedure if the terms are orthogonal to epistasis
features.
The maximum likelihood estimate of β is
βˆ = (X ′X)−1XY (2.2)
where βˆ is a p × r matrix of parameter estimates that follows a multivariate
normal distribution[162]
βˆ ∼ N
(
β, (X ′X)−1 ⊗ Σ
)
(2.3)
and the maximum likelihood estimate of Σ is
Σˆ =
1
n
(Y −Xβˆ)′(Y − hatβ) (2.4)
which is used to estimate the covariance of βˆ as
Σˆβˆ =
1
n
(X ′X)−1 ⊗
(
(Y −Xβˆ)′(Y −Xβˆ)
)
(2.5)
Since we now have estimates for the parameters as well as estimates for both
the mean and variance of each parameter under the null distribution, we can
apply the Fomac test-statistic.
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2.2.2 The Fomac Test Statistic
The F -test of Magnitude and Concordance (Fomac) statistic is the ratio of two
scaled chi-squared distributions. In its current form Fomac doesnt require the
covariance structure of βˆ, and it is sufficient to know individual parameter vari-
ances. Define A as a vector of length p
A = diag(Σˆβˆ) (2.6)
Define ¯ˆβj as the mean of the jth parameter across all traits
¯ˆ
βj =
1
r
r∑
i=1
βˆi,j
2
(2.7)
Magnitude (numerator): The numerator measures how far the models’ pa-
rameters are from the origin (where the null model is centered). The mean eu-
clidean distance of Beta from the origin (over r replicates) is scaled by a factor
accounting for two things: (1) the quantity involves the mean of models instead
of just a single model, so must be scaled by the inverse square root of r, and
(2) variance of the parameters needs to be unitized, so each parameter must
be scaled by its estimated standard deviation. This quantity is chi-squared dis-
tributed with p degrees of freedom.
p∑
j=1
1√
rAj
¯ˆ
βj ∼ χ2p (2.8)
Variance (denominator): The denominator measures how concordant the
model parameters are by using their sample variance. For each parameter, vari-
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ance is calculated across r replicates and scaled by the expected variance. Taking
the sum of these scaled variances across all p parameters yields a quantity that
is chi-squared distributed with p(r − 1) degrees of freedom.
p∑
j=1
1
Aj
r∑
i=1
(
βˆi,j − ¯ˆβj
)2
∼ χ2
p(r−1) (2.9)
F-statistic: The numerator and denominator described above are chi-
squared distributed. A ratio of chi-squared distributions, scaled by their re-
spective degrees of freedom, has an f - distribution with degrees of freedom the
same as those of the numerator and denominator, respectively. Therefore, tak-
ing the ratio of the previously established numerator and denominator, scaled
by their degrees of freedom, results in an f -statistic that simplifies to
(r−1)√
r
∑p
j=1
[ √
Aj
¯ˆ
βj∑r
i=1
(
ˆβi,j− ¯ˆβj
)] ∼ F
p,p(r−1) (2.10)
for which there is likely a more elegant linear algebra representation. Compar-
ing the f -statistic against the upper tail of the f -distribution produces a p-value.
2.2.3 Correcting for Correlated Traits
We have determined via simulations that when traits are correlated, the test
statistic deviates from the expected f-distribution by a multiplicative factor, such
that
Fexpected =
Fdeviated
median(Fdeviated)
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Therefore, a heuristic has been built into the Fomac framework which auto-
matically calculates this factor and corrects the test statistic. During the proce-
dure, the test statistic is calculated 10000 times using the traits of interest and
randomly chosen genotype sets of size g while being sure not to use any geno-
type sets that will subsequently be tested for concordant epistasis. Then, the
median of this test statistic is calculated and used to scale all subsequent tests
involving these traits.
2.2.4 Application to Epistasis/Generation of Epistasis Features
In order to specifically apply the FOMAC framework to epistasis detection, a
design matrix capturing genotype interactions must be generated (Figure 2.1-
top right). First, 2 ordinal codings must de defined in order to capture the 2 de-
grees of freedom captured by 3-category genotypes. Most commonly additive
and dominant codings are applied to capture the additive effects of alleles and
the independent effect of heterozygotes, respectively(citation). These codings
can be constructed to produce epistatic features that are orthogonal to the main
effects from which they are constructed, given certain distributions of samples
among genotype classes. The codings used here are independent of main effects
when genotype classes are balanced. The additive coding of the gth genotype is
defined as
Gg,a =

−1 if Gg = AA
0 if Gg = Aa
1 if Gg = aa
and the dominant coding of the gth genotype is defined as
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Gg,d =

−0.5 if Gg = AA
1 if Gg = Aa
−0.5 if Gg = aa
To create a design matrix capturing all epistatic effects, all possible interac-
tions between the involved genotypes are considered. In the case of two-way
epistasis, this generates 4 epistatic features for the design matrix. An epistasis
linear regression model has the form
Y = βa,dG1,aG2,d + βd,aG1,dG2,a + βd,dG1,dG2,d + 
where β represents the strength of a genetic effect and  is error.
The full epistasis linear regression model, which includes main effects (terms
2-5) and all orders of epistasis up to the maximum order (terms 6-9) has the form
Y = β0 + β1,aG1,a + β2,aG2,a + β1,dG1,d + β2,dG2,d + βa,aG1,aG2,a
+βa,dG1,aG2,d + βd,aG1,dG2,a + βd,dG1,dG2,d + 
It is important to note that estimations of these epistasis parameters depend
on the choice of coding and parameterization for this model. However, all fully
parameterized (pure) epistasis models of this form will capture the same range
of epistatic effects. In comparison, all full epistasis models which include main
effects may not be equivalent. PLINK uses an epistasis model that includes
additive main effects but is not fully parameterized since only the additive main
effects and additive-by-additive epistasis terms are included in the regression.
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2.2.5 Comparing Performance
Performance of Fomac was compared to other methods designed to detect 2-
way epistasis in eQTL datasets: PLINK[184], CAPE[224], a random forest-based
interaction-scoring method, multivariate and univariate versions of the linear
regression model used by Fomac, and the combined p-values from the univari-
ate regression[132]. Scores for the univariate method were p-values calculated
by performing the Wald test[72] on all epistasis parameters from the same epis-
tasis model used by Fomac. Scores for the multivariate method were p-values
calculated from the Wilkss lambda test statistic generated by fitting the same full
epistasis model jointly to all traits. Since PLINK and the univariate linear regres-
sion model produced a p-value for each trait, only scores from the first trait were
used in order to represent the performance of methods that use a single dataset
for epistasis discovery. Additionally, p-values from PLINK and the univariate
linear regression model were combined using Fishers combined probability test
in order to represent the performance of methods that analyze multiple traits
separately but afterwards consider results jointly across traits. The tree-based
interaction-scoring method was a simple adaptation of SNPInterForest[244] im-
plemented in the R statistical programming language. Briefly, the idea is to
regress a trait on all genotypes using random forest, and look for instances
where a set of genotypes co-occurs on the same branch more often than would
be expected by random chance. Fomac was also tested in the 3- and 4-way epis-
tasis settings, but PLINK and CAPE had to be excluded from the comparison
since they do not accommodate greater than 2-way epistasis. Some methods
were excluded from all comparisons because they returned scores for a group
of genotypes or scores for each phenotype, thus rendering their output incom-
patible with the performance metrics used in this comparison[249].
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2.2.6 Simulations
We simulated 50 datasets (sample size = 900), each containing 15 genotypes and
100 sets of 4 traits, which had been generated from an epistatic effect between a
random pair of genotypes
Yr = βa1a2Ga1Ga2 + βa1d2Ga1Gd2 + βd1a2Gd1Ga2 + βd1d2Gd1Gd2 + r (2.11)
Where Yr is the rth trait, Gi,d is the additive coding of the ith randomly se-
lected genotype coded -1 for heterozygous minor, 0 for homozygous, and 1 for
heterozygous major, Gi,d is the dominant coding of the ith randomly selected
genotype in the set of interacting genotypes coded -0.5 for heterozygous minor,
1 for homozygous, and -0.5 for heterozygous major, and epsilon is a multivariate
Normal error term with diagonal covariance matrix. Genotypes were simulated
with evenly distributed allele-classes (resulting in minor allele frequency of 0.5),
and no two genotypes had a correlation greater than 0.2.
For each dataset, there were 10500 possible cross-trait epistasis tests, 100 of
which were condition positive. For every method, scores were used to pro-
duce a receiver operating characteristic (ROC) curve, and ROC curves from all
50 datasets were averaged to produce a single smoothed ROC curve for each
method. Area under curve (AUC) was also calculated for all datasets, and the
distribution of AUCs was used to produce a box plot for each method. Per-
formance was assessed in this manner for 6 sets of parameters, spanning all
combinations of number of traits (r) = 4/8 traits and epistasis order (g) = 2/3/4
genotypes (Table 2.1). In order to eliminate the increase in genotype class spar-
sity that would otherwise occur when increasing epistasis order (2 genotypes =
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9 classes but 3 genotypes = 27 classes), sample sizes were scaled such that the ra-
tio of sample size to number of possible genotype classes was 100 samples/class
in all simulations.
Table 2.1: Simulation Parameter Configurations
2.2.7 Application to Human Data
We performed an analysis for concordant cross-tissue eQTL epistasis on adi-
pose, lymphoblastoid cell line (LCL), and skin datasets obtained through the
Multiple Tissue Human Expression Resource (MuTHER) project[75]. We kept
all 618 samples that had genotypes and expression in all three tissues and geno-
types (Figure 2.2A), and all 28827 genes that were measured and expressed in all
three tissues (Figure 2.2B). Traits were adjusted for covariates by regressing each
trait on age and appropriate tissue-specific covariates and keeping the residuals.
Mean centering and variance standardizing had little effect on the resulting p-
values (design matrix contains intercept term, which takes care of any nonzero
mean), so these steps were skipped. In order to help keep genotype classes bal-
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anced, we filtered out genotypes that had a minor class frequency (MCF) lower
than 0.25 (fewer than 25% of the total samples in each of the three genotype
classes). While this does not guarantee balanced classes, it limits the extent to
which classes would be unbalanced. Genotypes were taken from the TwinsUK
consortium, and the 18416 genotypes not requiring imputation and with MCF
> 0.25 were kept.
Figure 2.2: Venn Diagram of Sample/Gene Overlap Across Datasets
For each of 28827 sets of 3 traits (single gene measured 3 times in different
tissues), main effects from all genotypes were calculated, and a set of 100 in-
dependent (Pearson correlation < 0.2) genotypes was assembled from the top
main effect scores pooled from all tissues. The set of traits was then tested for
concordant epistasis with all pairs of the set of independent genotypes. In very
rare cases (3.6×10−3% of the time) X’X was not invertible and a regression could
not be performed, so not all genotype pairs were used for every gene. A total of
142,688,467 total tests were performed. Analogous tests for epistasis were also
carried out with the only alteration occurring in the parameter estimation pro-
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cess where the design matrix included the same main effect features that were
used to detect main effects in the previous step.
2.3 Results
2.3.1 Simulations demonstrate sensitivity to inter-trait correla-
tions and unbalanced designs
Simulations were performed to examine the test statistic’s behavior under devi-
ation from optimal conditions. We determined that (1) correlations among traits
in standard sample space cause correlations among traits in parameter space as
well, which causes the statistic to deviate from its expected f-distribution. This
likely occurs because the statistic assumes that samples in parameter space are
derived from independent multivariate Normal distributions, and this assump-
tion is violated with correlated traits. We also determined that (2) if samples are
distributed unevenly among the 9, 27, 81, etc. genotype classes for 2-, 3-, and 4-
way epistasis, respectively, correlations appear among parameters in parameter
space, which also causes the statistic to deviate from its expected f-distribution.
This likely occurs because each full set of epistasis features is only orthogo-
nal for a given distribution of samples among the genotype classes - the most
commonly used sets of epistasis features usually exhibit orthogonality or near-
orthogonality in settings where samples are nearly evenly distributed among
the genotype classes (citations spanning all codings that have been used). In
order to avoid skewing the test statistic, Fomac was applied in situations where
samples were sufficiently evenly distributed among genotype classes to avoid
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skewing the test statistic.
2.3.2 Performance Comparison
In our analysis on simulated data, we tested the ability of Fomac and compara-
ble methods to detect epistasis when given multiple traits generated from con-
cordant epistatic effects. We produced ROC curves averaged over 50 datasets
(Figure 2.3 and calculated area under each curve to produce a distribution of
ROC AUCs for each method (fig 4b, fig S1b). As assessed by mean AUC, meth-
ods ranked the same across all parameter configurations, with performance or-
dered (1) Fomac > (2) multivariate LM ∼ combined univariate LM > (3) com-
bined PLINK > (4)univariate LM > (5) PLINK > (6) random forest method >
(7) CAPE. It is not entirely clear why CAPE is the only of the multivariate meth-
ods (Fomac, multivariate LM, CAPE) that performed worse than both univari-
ate methods (PLINK, univariate LM). CAPE transforms traits into eigentraits
and keeps only some top number of eigentraits, meaning that some informa-
tion from the set of traits may be lost and will therefore be unavailable to the
epistasis detection task - but the 3 eigentraits should still capture more infor-
mation than just a single one of the original traits, especially since traits in the
simulations were not highly correlated..The random forest method is expected
to thrive in conditions with thousands of genotypes, when exhaustively testing
all combinations becomes restrictive. In this setting, exhaustive testing is not a
statistical or computational problem but the noise level is, so random forest has
no advantage over the other methods. PLINK also suffers because it only tests
for one of the four epistatic effects, and is therefore missing out on the other
three effects that may exist. While containing the optimal parameterization for
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detecting the effects that are present, the univariate LM is only using one of the
traits (as most current methods do). Combined PLINK and combined univariate
LM both do substantially better than when only one dataset is used to produce
a score. This result also operates as a sanity check to make sure that at least one
other method is able to leverage the concordant epistasis in these datasets.
2.3.3 Human Data
Quality Control
We used the Fomac framework to analyze gene expression from MuTHER[168]
and genotypes from TwinsUK[155] datasets. Fomac was able to handle inter-
correlated non-Gaussian traits, the presence of main effects, and tests that wer-
ent strictly independent due to testing all possible combinations of a relatively
small group of genotypes. While restricting genotypes to those with rela-
tively evenly distributed classes is not ideal in practice, this step is necessary to
demonstrate that the Fomac framework can handle all other characteristics of
real biological data and return true p-values (with demonstrated uniform null
distribution), as shown by global QQ plots (Figure 2.4). Since we expect concor-
dant epistasis to produce correlations among traits, it is essential to be able to
test correlated traits in a controlled manner. The heuristic for this correction is
not well understood theoretically but works well in practice, in both simulated
and real data scenarios. Since main effects were used to identify the group of
candidate epistatic genotypes, it was essential that the epistasis features be or-
thogonal to main effects or else the resulting QQ plots would be inflated (lower
p-values than expected under the null hypothesis) and we would risk identify-
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Figure 2.3: Simulation ROC Performance. Parameters: r = 4, g = 2, n =
900
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ing spurious associations. Due to the choice of genotype coding, all 4 epistasis
features in the model were theoretically orthogonal to the main effect codings in
the case of evenly balanced genotypes classes, and nearly orthogonal in the case
of nearly balanced genotype classes. This characteristic assured that main ef-
fects between genotypes and traits would not be detected by our epistasis tests,
so that any identified effects were purely epistatic. The group size of candidate
epistatic genotypes for a given gene (chosen either by main effects or proximity
to gene) also impacted the results of this study. Group sizes less than 50 caused
a noticeable dependence among tests for epistasis, which is why the group size
of 100 was chosen. A big challenge was to balance using enough genotypes in
a group while minimizing the total number of tests performed so as to maxi-
mize power to detect small epistatic effects among genetic loci exhibiting main
effects.
Figure 2.4: Global QQ Plots for uncorrected (left) and main effect-
corrected (right) p-values.
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Significant Tests
Of the 142,693,650 total tests performed genome-wide, none were globally sig-
nificant at the Bonferroni or Benjamini-Hochberg level at α = 0.05, which is
consistent with the prevailing knowledge that exhaustive pairwise searches
for epistasis severely limit statistical power. A common approach for ad-
dressing the limited power of genome-wide analyses is to employ a gene-wise
cutoff[10, 120, 221, 34, 119]. Since each gene in an eQTL can be thought of as its
own GWAS, the idea is to look next for tests that might not have had enough
power to meet the global cutoff but show up as hits when only a single gene
is considered[124]. Tests which meet the gene-wise Bonferroni cutoff in genes
that have well-controlled QQ plots may still be useful. This analysis identified
2754 gene-wise Bonferroni-significant tests. While we don’t suggest that all of
these tests represent true positive signals, more tests are significant than would
be expected by chance, suggesting that there could be a true signal present.
Of the 2754 gene-wise significant tests, 62 were significant both with and
without correcting for main effects of the involved genotypes. 1304 had lower
p-values after correction than before correction for main effects. 1 involved two
cis-loci, 45 involved cis-trans loci, and 2708 involed two trans- loci. 2656 of these
significant tests would not have been picked up by PLINK or Fish et al.[54] even
when using the cutoff that would result from only considering one dataset at a
time. Normally, one would need to perform r times as many statistical tests if
testing datasets separately, so this cutoff would normally be more strigent.
An example of concordant epistasis discovered by Fomac is displayed in Fig-
ure 2.5. This gene-wise Bonferroni-significant concordant epistasis is not a hit
before correcting for marginal effects (p = 4.34 × 10−3, green dot in top left QQ
48
plot of Figure 2.5), but afterwards the p-value for this concordant epistasis is
p = 8.75× 10−9, green dot in top right QQ plot of Figure 2.5). For reference, the
global Bonferroni cutoff is 3.50 × 10−10. The gene expression of ILMN 1749403
was corrected for batch effects, age, and main additive and dominance effects of
genotypes rs1924458 and rs12708504, and the mean expression for each of the 9
genotype classes (min samples per genotype class was 35 here) was plotted (bot-
tom three GP maps in Figure 2.5). An epistatic effect that is concordant across
all three tissues (adipose, LCL, skin) is present visually. Since main effects have
been corrected out of gene expression, this pattern must represent concordant
pure epistasis.
2.4 Discussion
Here we presented Fomac, a novel statistic designed to detect instances of con-
cordant epistasis among multiple quantitative traits. The versatility and utility
of this statistic was demonstrated in simulations and real data analysis. In sim-
ulations, 6 parameter configurations were tested including higher order epista-
sis and many traits. In human data analysis, the Fomac framework produced
a well-calibrated test statistic and many candidates for statistical epistasis that
would not be identified by other approaches.
The large p, small n case presents an extreme challenge in epistasis detection,
requiring at least two conceptual modules in the process of epistasis discovery.
Since the approach outlined here only approaches the ”identify” module, it de-
pends on success in the initial ”search” module. It seems that the primary limi-
tation of this study has been the first module which I call the ”search” module.
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Figure 2.5: Gene-wise QQ Plots for unadjusted (top left) and main-effect
adjusted p-values (top right)
This is actually good news because it means that Fomac can be combined with
the plethora of methods designed to address the difficulties of searching for a
needle in a haystack.
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CHAPTER 3
WHOLE-METHYLOME ANALYSIS OF CIRCULATING MONOCYTES IN
ACUTE DIABETIC CHARCOT FOOT REVEALS THE PRESENCE OF
DIFFERENTIALLY METHYLATED GENES INVOLVED IN MIGRATION,
DIFFERENTIATION AND FORMATION OF OSTEOCLASTS
Objectives: Increased differentiation of monocytes into osteoclasts, leading to
bone resorption is the hallmark of Charcot foot (CF) disease.
Research design and methods: We studied the whole-methylome (WM) of
circulating monocytes in 18 patients with type 2 diabetes (T2D) and acute CF, 18
T2D patients with equivalent neuropathy and 18 T2D patients without neuropa-
thy, using the enhanced reduced representation bisulfite sequencing technique.
Results: WM analysis demonstrated that CF monocytes are differentially
methylated compared to non-CF monocytes (p = 5.1 × 10−7). However, analy-
sis comparing T2D patients to T2D patients with neuropathy did not show any
significant differential methylation. 13 out of > 1.2 million individual CpG sites
had p-values lower than the Benjamini-Hochberg cutoff when comparing CF
patients to non-CF patients. Analysis of individual genes showed that 114 out of
21,542 genes were differentially methylated for CF versus non-CF. Out of those
genes, 23 genes are involved in the migration process during monocytes differ-
entiation into osteoclasts or indirectly involved in osteoclast formation through
the regulation of inflammatory pathways. Finally, we demonstrated association
between DNA methylation and gene expression in cis and trans-association.
Interestingly, PPP2R5D was the only gene both differentially methylated and
expressed (cis-association) in CF patients. We also identified 27 genes with sig-
nificant changes in methylation between CF and non-CF that were significantly
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associated with expression in 24 genes (trans-association).
Conclusion: In total, our findings unveil a possible role of circulating mono-
cytes HM in the pathogenesis of CF, with the ultimate goal of finding means to
modulate or prevent it.
3.1 Introduction
Charcot foot (CF) disease is a devastating complication of diabetes, associated
with an increased risk of soft tissue infections, foot ulcers and amputations
[198]. It is characterized by an exaggerated bone resorption [246], believed to
be induced by an increased numbers of osteoclasts and their activity [137, 175].
Osteoclasts are derived from monocytes, mostly from CD14+ that have the high-
est potential to differentiate, following a differentiation pathway that results in
mature functional osteoclasts whose role is to activate bone resorption [225].
Epigenetics modulate the differentiation of many adult cell types from pro-
genitor or primary cells with whom they share the same DNA sequence, and
play an important role in gene transcription through 3 major components: DNA
methylation, non-coding RNAs, and post-translational changes of histone pro-
teins [15]. Methylome, which is the set of nucleic acid methylation modifica-
tions in an organisms genome or in a particular cell [14], also participate in the
pathophysiology of several diseases by controlling cellular differentiation pro-
cesses and transcriptional activities of genes [182]. Therefore, we hypothesized
that the methylome of circulating monocytes in patients with acute diabetic CF
could be involved in the pathogenesis of the disease.
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In here, we report the presence of differentially methylated genes involved
in migration, differentiation and formation of osteoclasts in circulating mono-
cytes of type 2 diabetes (T2D) patients with acute CF, compared to T2D patients
without CF.
3.2 Methods
3.2.1 Subjects
Eighteen T2D patients with acute CF, matched for age, gender, BMI and HBA1C
with 18 T2D patients with neuropathy but no CF and 18 T2D without neuropa-
thy or CF were studied (Table 3.1). CF patients were recruited from the podiatry
clinic at Hamad Medical Corporation (HMC), Doha- Qatar. All other patients
were recruited from the department of endocrinology and diabetes at HMC.
Acute CF was diagnosed according to the American Diabetes Association
and the American Podiatric Medical Association task force [198]. Patients had
to have a red swollen foot with increased local temperature of more than 20 C
compared to the contralateral foot with X-Ray evidence of acute CF. Foot tem-
perature was measured using FLUKE Ti32 thermal imager (Fluke Corporation -
USA). All patients with acute CF had neuropathy, diagnosis of which was based
on the vibration perception threshold (Neurothesiometer NU-1, Horwell- UK)
on the great toe being >25V [245]. Among those, 5 had dislocations or subluxa-
tions, 4 had fractures, 5 had periosteal reactions and 4 had bone destruction on
X-ray.
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Table 3.1: Baseline characteristics of the participants included in the
study. Diabetes but no neuropathy (D), diabetes with neuropa-
thy (DN), and diabetes with both neuropathy and Charcot foot
(DCh). Data are represented as mean (standard deviation). p-
values were calculated with ANOVA test.
The study was approved by the institutional review boards of Weill Cornell
Medicine-Qatar and HMC (13-00031 and 14-14054, respectively). All partici-
pants provided written informed consent. The study was conducted in accor-
dance with the 1964 Declaration of Helsinki and was registered at clinicaltri-
als.gov (NCT02316483).
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3.2.2 Monocytes Isolation and DNA/RNA Extraction
10 mL of blood was withdrawn from peripheral venous puncture from each par-
ticipant. Peripheral blood mononuclear cells (PBMCs) were first isolated from
whole blood and stained with the mouse anti-human IgG2b CD14 APC and
the mouse anti-human IgG1 CD16-PE (BD bioscience). Monocytes were then
sorted using FACSAria2 flow cytometer (BD Biosciences). Purity of the sorting
was controlled after each sorting (Figure B.1). DNA and RNA from monocytes
were extracted (Allprep DNA/RNA mini kit Qiagen) and stored at -80C, than
shipped to the epigenomics core at Weill Cornell Medicine (WCM) and the New
York Genome Center (NYGC) using dry ice for sequencing.
3.2.3 Enhanced Reduced Representation Bisulfite Sequencing
and Data Processing
Enhanced Reduced Representation Bisulfite Sequencing (ERRBS) libraries, se-
quencing, data alignment and methylation calls were generated at the Epige-
nomics Core at WCM as described in Garrett-Bakelman et al [64].The published
protocol was modified as follows: samples were size selected on a 2% agarose
cassette using a Pippin HT (Sage Science, Beverly, MA), and two size fragment
lengths of 240375 bp and 375550 bp were recovered and further processed. Sam-
ples were checked for quality via two methods: (1) the distribution of CpG site
coverage (Figure B.2A) - experiments that are suffering from PCR duplication
bias will have a secondary peak to the right of the primary peak, and (2) distri-
bution of methylation -values (Figure B.2B) this histogram should have a peak
towards zero methylation and a peak towards methylation of one [4].
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Two analysis approaches were carried out:
(1) CpG site analysis 1,240,581 CpG sites which had coverage of at least 10*
across all patients were used.
(2) Gene-mapped analysis For each gene, CpG sites within an interval 2 kb
upstream and 2 kb downstream of the transcription start site (TSS - taken from
ENSEMBL annotation) were used to determine a methylation level for the gene
since a majority of CpG islands are within 2kb of TSS [258]. The methylation
of a gene was calculated as the mean methylation of measured sites within the
interval, weighted by the coverage at each site [3]. Twenty-one thousand six
hundred thirty-four genes had at least 1 CpG site within the mapping interval
for all patients. More information regarding CpG sites and mapping to genes
can be found in Table 3.2.
DNA from circulating monocytes was sequenced in three distinct batches.
In order to determine if a batch effect should be considered in subsequent anal-
ysis. The first two principal components of the gene-mapped CpG data were
plotted and colored by batch (Figure B.2C-D). It was determined that batch had
affected the methylation measurements and should therefore be accounted for
in statistical analysis.
3.2.4 Differential Methylation
Patients were placed in one of three groups:
D: group with diabetes but no neuropathy (n = 18)
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Table 3.2: Genome-wide methylation study on Charcot foot. In order to
identify methylation differences specific to Charcot foot, circu-
lating monocytes were isolated from blood of patients with dia-
betes but no neuropathy (D), diabetes with neuropathy (DN),
and diabetes with both neuropathy and Charcot foot (DCh).
CpG methylation data was produced by enhanced reduced rep-
resentation bisulfite sequencing (ERRBS). Each group has n =
18 and patients are matched for age, gender, BMI, and HbA1c
across all groups such that these covariates were not signifi-
cantly different among groups (rightmost column). Methylation
of a gene was calculated as the mean (weighted by coverage)
observed CpG sites within 2kb upstream and 2kb downstream
of transcription start site, as determined by Ensembl annotation.
The bottom portion of the table provides summary statistics of
the number of CpG sites within the mapping interval of a gene,
and the total number of CpG sites with coverage of at least 10
(sites with coverage less than 10 were not used).
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DN: group with diabetes and neuropathy but no Charcot foot (n = 18)
DCh: group with diabetes and Charcot foot (n = 18)
In order to test for methylation differences that were specific to Charcot foot,
patients were also grouped as either having Charcot foot (DCh) or not having
Charcot foot (DDN, n = 36). DDN grouping is of primary interest for two rea-
sons: (1) it will tend to identify genes that are different due to CF (which in-
volves neuropathy) without identifying genes that are different due to purely
neuropathic reasons, and (2) it will provide more total samples and therefore
greater statistical power than testing for differences between CF and either one
of the non-CF groups. This is true as long as the two subgroups being grouped
together are not significantly different from each other. Therefore, in order to
statistically justify this grouping, differential methylation was also tested for
the three possible pairings of the three groups: D versus DN, D vs DCh, and
DN vs DCh (Figures B.3 & B.4). If methylation differences are detected in the
D vs DCh and DN vs DCh comparisons but not in the D versus DN compar-
ison, then grouping non-CF patients together for comparison with CF is justi-
fied. Singular value decomposition [49] was performed for both methylation
of the 1,220,216 autosomal CpG sites and methylation of the 21,049 autosomal
genes. Sex chromosomes were excluded just for this portion of the analysis
so that the samples did not stratify based on gender. The left-singular vectors
represent independent methylation features that can capture large amounts of
variance from the original data. Since the left-singular vectors capture much
of the variance from the original data and represent a signal from many genes,
they can be considered a good proxy for the whole methylome. In order to test
for a difference in group methylomes the first three left-singular vectors from
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(Figures 3.1B & 3.1D) were regressed on covariates (batch) and group using
multivariate linear regression (this was done separately for the CpG site and
gene-mapped approaches), which tests for a multivariate difference between
group. Next, all 1,240,581 CpG sites and 21,634 individual genes were tested
for differential methylation by regressing a site/gene on covariates (batch) and
group using an analogous univariate linear regression methodology which tests
for a univariate difference between group means. Both WM differential methy-
lation and individual site/gene differential methylation for both CpG site and
gene-mapped methylation were tested for 4 groupings of patients: DDN/DCh,
D/DN, D/DCh and DN/DCh. P-values were produced using a likelihood ratio
test of the model containing group versus the model not containing group. Lin-
ear regression has been shown to possess similar statistical power to Wilcoxon
rank sum test, Kolmogorov-Smirnov test, permutation test, empirical Bayes
method, and bump hunting method in simulated DNA methylation studies
with sample sizes greater than n = 12 in each group [127]. Significance was
assessed using a false discovery rate of α = 0.05 for both Bonferroni and BH
multiple test correction procedures. In order to compare the differential methy-
lation findings to what would be expected by chance, each differential methyla-
tion analysis was carried out an additional 10 times on permuted data. A sam-
ples group status is permuted in order to disrupt any association between group
and methylation. The association between methylation and batch is maintained
since this association is required for appropriate covariate correction. These per-
mutation analyses give a sense empirically of how far our original differential
methylation p-values are from what we would observe if there were truly no
association between group and methylation [46]. The results of this comparison
between original and permuted data are displayed in quantile-quantile (QQ)
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plots (Figure B.5).
3.2.5 Gene Expression Data
Data generation and filtering - DNA was synthesized from 10ng of good quality
total RNA (RIN>7) using SMART-SEQ v4 Ultra Low Input RNA Kit (ClonTech)
at the New York Genome Center (NYGC) according to the manufacturers pro-
tocol with 8 cycles of amplification. Resulting cDNA was cleaned up with a 1:1
volume ratio of AMPURE XP beads (Beckman) and evaluated on the Fragment
Analyzer using a High Sensitivity DNA Assay (AATI). Full-length cDNA was
sheared to an average size of 350bp fragments using Adaptive Focused Acous-
tics (AFA) technology (Covaris, LE220). Illumina-compatible libraries were pre-
pared with KAPA Hyper Prep Kit (Roche) and Illumina dual indexed adapters
according to the manufacturers specifications with 9 cycles of amplification. The
libraries were quantified by picogreen assay and NGS assay (Fragment Ana-
lyzer, AATI) and sequenced on an Illumina HiSeq2500 sequencer (v4 chemistry,
v2 chemistry for Rapid Run) using 2 x 50bp cycles. RNA-sequencing analysis
- The reads were aligned with STAR (version 2.4.0c), and genes annotated in
Gencode v18 were quantified with featureCounts (v1.4.3-p1). All the genes with
less than one read across all the samples were not taken into the consideration
which resulted with total set of 16007 genes for 30 samples. Normalization of
expression was performed using the Bioconductor package DESeq2 using the
rlogTransformation function [135].
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Association between DNA methylation and gene expression in
Charcot foot patients
RNA sequencing was done at NYGC. We tested the association between DNA
methylation (independent variable) and log2 transformed gene expression (de-
pendent variable) using linear model in which diseases status and batch ef-
fect where used as covariates. We included only BH significant genes on
methylome-wide level (Table 3.1); n=2,488 genes) against their transcripts in
our linear regression analysis. Since a total of 1,326 genes were common in
both data sets, we performed p-value correction based on BH criteria for 1,326
genes. Subsequently, to identify potential trans effect between methylation and
expression in CF, as well as to identify all the other associations relevant to CF
condition we perform multiple test correction included all methylated and all
expressed genes. As we did not identify a large number of significant CpG sites
at methylome-wide level, only methylation-expression association on gene level
were considered in these analyses. Gene ontology (GO) enrichment analysis
[254] was performed using STRING database. STRING is a database of known
and predicted proteinprotein interactions, direct (physical) and indirect (func-
tional) associations [217].
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3.3 Results
Combining diabetic patients with and without neuropathy
This analysis consisted of 4 ways of assessing differential methylation, pro-
duced by all combinations of 2 different ways of looking at methylation (in-
dividual CpG site methylation and gene-mapped methylation), and 2 different
ways of looking at differences in methylation (wholemethylome and individual
site/gene). For each way of assessing differential methylation, four compar-
isons were carried out: DDN/DCh, D/DN, D/DCh, and DN/DCh. The first
grouping provides the primary result of interest, since it will identify differential
methylation that is specific to CF and not due to either diabetes or the neuropa-
thy that can afflict acute CF disease. However, in order to justify this grouping,
it needs to be shown that diabetic patients with and without neuropathy can
be considered similar enough to group together. The last three comparisons are
therefore used to establish the similarity of the D and DN groups relative to the
differences evident in both the D/DCh and DN/Dch comparisons.
Table 3.3 shows that the D/DN comparison identified 1 differentially methy-
lated gene, 0 differentially methylated CpG sites, and was not able to stratify the
top 3 principal components in either the CpG site (p = 0.92) or gene-mapped
(p = 9.6× 10−2), insignificant after multiple test correction) approaches. On the
other hand, the D/DCh and D/DN comparisons identified several Bonferroni
significant and several hundred BH significant differentially methylated genes,
and both comparisons were able to stratify the top 3 principal components in
both approaches (Table 3.3). These results demonstrate that patients with dia-
betes are not significantly different than patients with diabetes and neuropathy
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when assessed for differential methylation in circulating monocytes using the
discussed methods. Therefore, it is valid to group D and DN together to use as
a single group to compare with CF patients using the same methods that were
used to establish similarity of the non-CF patients.
Table 3.3: Differential methylation results for 4 groupings of patients.
Results of 4 differential methylation approaches: methylome-
wide differential methylation (p-value derived from multivari-
ate linear regression fit using the first 3 principal components as
dependent variables as well as batch and group as independent
variables) and individual site/gene differential methylation for
both CpG site (top 3 rows) and gene-mapped methylation (bot-
tom 3 rows). For each approach four group comparisons were
made, represented by the four columns of the table which are
labeled based on the two patient groups that were compared.
3.3.1 Comparing Diabetic Patients With and Without Neuropa-
thy to Patients With Charcot Foot
WM analysis (which looks at linear combinations of many CpG sites or genes)
demonstrates that CF monocytes are differentially methylated when compared
to non-CF monocytes (DDN/DCh) in both the CpG site (Figure 3.1A-B) and
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gene-mapped (Figure 3.1C-D) approaches. Individual genes reinforce this re-
sult with 114 out of 21,634 genes having p-values lower than the Bonferroni-
significant cutoff of p = 2.3 × 10−6 for DDN/DCh (Figures 3.1E & B.5E). 13
out of 1,240,581 individual CpG sites had p-values lower than the BH cutoff of
p = 5.2−7 for DDN/DCh (Figures 3.1F & B.5A). This particular way of assess-
ing differential methylation suffered from a very stringent multiple test correc-
tion since over a million CpG sites were tested individually. From a theoretical
standpoint, power to detect a given effect size decreases as a researcher per-
forms more tests to identify the effect. Therefore, it makes sense that fewer
individual CpG sites than genes were identified as significantly differentially
methylated.
Permutation analysis demonstrates that the effect of group on methylation
vanishes when group is permuted. This analysis allows the structure of co-
variates with respect to methylation to remain intact while disrupting any as-
sociation between group and methylation. These permutation analyses can be
thought of as a way of accessing the empirical null distribution, which isnt al-
ways guaranteed to match the theoretical null distribution [16]. When the em-
pirical null p-value distribution matches the theoretical null p-value distribu-
tion (uniform) or is skewed towards 1, the true empirical p-values are expected
to be at least as low as the p-values that were calculated. All eight QQ plots
(Figure B.5) show that permutation analyses return p values either matching
the uniform distribution or skewed towards 1 (this is represented in the plots as
the cyan line being below the dashed gray line). This result serves to justify the
statistical methodology that was used. The QQ plots (Figures B.5B & B.5F) also
serve as a way of further confirming that D and DN do not have different methy-
lation patterns since inspection reveals that the original p-values overlap with
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Figure 3.1: CpG site and Gene-mapped differential methylation in patients with
diabetes and CF compared to patients with diabetes but no CF. A.
The first two principal components of autosomal gene methylation,
as calculated by singular value decomposition. Samples are colored
by group: diabetes in blue, diabetes with neuropathy in purple, and
diabetes with CF in red. B. Wholemethylome signal as captured
by the first three principal components (horizontal axes) of the dis-
played subset of patients. Violin plots representing the distribution
of a particular patient group along a principal component are adja-
cent to their corresponding group. C. The first two principal compo-
nents of autosomal gene methylation, as calculated by singular value
decomposition. Samples are colored by group: diabetes in blue, di-
abetes with neuropathy in purple, and diabetes with CF in red. D.
Whole-methylome signal as captured by the first three principal com-
ponents (horizontal axes) of the displayed subset of patients. Violin
plots representing the distribution of a particular patient group along
a principal component are adjacent to their corresponding group. E.
Chromosomal distribution of gene methylation differences. For each
gene, the significance is displayed on the y-axis as the log10 of the
p-value. The results are ordered along the x-axis by chromosome,
with each bar representing a different chromosome. The Bonferroni
and BH p-value thresholds (α = 0.05) were 2.3 × 10−6 (yellow line)
and 5.8 × 10−3 (green dashed line), respectively. F. Chromosomal
distribution of gene methylation differences. For each gene, the sig-
nificance is displayed on the y-axis as the log10 of the p-value. The
results are ordered along the x-axis by chromosome, with each bar
representing a different chromosome. The Bonferroni and Benjamini-
Hochberg p-value thresholds (α = 0.05) were 4.0×10−8 (yellow line)
and 5.2× 10−7 (green dashed line), respectively.
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the permutation p-values. The differential methylation of CF compared to non-
CF foot using both CpG site and gene-mapped approaches also demonstrate
that the way methylation was mapped to genes is at least as effective at captur-
ing discriminatory information as looking at individual CpG sites. This isnt a
reference to the number of significant sites or genes identified, instead it has to
do with the actual p values. Comparing Figures 3.1E and 3.1F, it is evident that
the mapped approach is producing p values at least as low as those produced
from the CpG site approach. This finding matters because it means that this ap-
proach has largely been able to avoid the pitfall of combining discordant signals
from nearby CpG sites, which would be detrimental to the discrimination task.
Therefore, we focused the rest of the analysis on the gene-mapped differential
methylation.
3.3.2 Gene-mapped Differential Methylation in Patients with
Diabetes and Charcot Foot Compared to Patients with Di-
abetes But no Charcot Foot
114 out of 21,634 genes were differentially methylated in CF patients compared
to non-CF monocytes when looking at the gene-mapped methylation. When we
take a closer look to the 114 genes one by one, we notice that 37 genes out of the
114 Bonferroni-significant genes differently methylated for CF versus non-CF
have an unknown function. Most of the 114 genes presented a hypermethyla-
tion (86%) in CF patients (Figure 3.2A). Figure 3.2B represents the 10 top hyper-
methylated (top part, red) and hypomethylated (bottom part, green) genes in
CF patients.
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Figure 3.2: Gene analysis for gene-mapped differential methylation in pa-
tients with diabetes and Charcot foot compared to patients
with diabetes but no Charcot foot. A. Graphic representa-
tion of the number of hypo- and hyper-methylated genes. B.
Representation of the 10 top hypermethylated (top part, red)
and hypomethylated (bottom part, green) genes in CF patients
compared to patients with diabetes but no Charcot foot. C-
D. Networks of altered genes mapped differential methylation
created by IPA. The hypothetical networks generated by IPA
based on the molecular relationships, interactions, and path-
way associations between the methylated candidate genes are
shown in a graphical representation.
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IPA global analysis of the 114 Bonferroni-significant genes differently methy-
lated for CF versus non-CF revealed significant enrichment of the category
Amino Acid Metabolism, molecular transport, Small molecule Biochemistry
(Figure 3.2C) as well as the category involving Embryonic development, or-
ganismal development, Tissue Morphology (Figure 3.2D). This observation in-
dicates that circulating monocytes in CF patients seem to be ready for differen-
tiation. Both enriched classes are coherent with the experimental design.
A total of 23 genes could be involved directly or indirectly in monocyte dif-
ferentiation into osteoclast which represent around 15% of the total genes dif-
ferentially methylated in CF patients (and around 30% of the gene with known
function). One of the top hits in this list is MAPK11 that is known to enhance
osteoclastogenesis and bone resorption in breast cancer [79].
3.3.3 Association between DNA methylation and gene expres-
sion in Charcot foot patients
Abnormal DNA methylation can result in aberrant gene expression [236].
Therefore, we investigated gene expression in our samples and try to associate
it with the DNA methylation. First, we identified 2488 significant genes with
BH correction (BH p-value cutoff = 5.7−3). Of these 2488, 818 genes were down-
regulated and 1670 upregulated. Gene methylation can have 2 different types
of associations with gene expression: i) Local association (cis-) where one differ-
entially methylated gene (A) will have an effect on the exact same gene (A) on
expression level, or ii) Distal association (trans-) where one differentially methy-
lated gene (A) will have an effect on a different gene (B) on expression level.
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In order to test for cis- and trans-effect of the methylation on gene-expression,
we performed linear-regression for 2488 genes, treating gene expression as de-
pendent variable, and methylation as independent variable using disease status
and batch effect as covariates. PPP2R5D was the only gene detected with a cis-
association with expression. The correlation coefficient beta is 4.4, so expression
and methylation of this gene are positively correlated. Both methylation and
expression are increasing in CF patients. For the trans-association, we identi-
fied 27 genes out of 2488 genes with significant changes in methylation between
CF and non-CF that were significantly associated with expression in 24 genes.
Four (MTCL1P1, ITGAL, DHX40, GFOD2) of these genes were hypomethylated
when comparing CF to non-CF samples, while the others were hypermethylated
(Figure B.4). We created a minimum network of protein-protein interaction us-
ing the 27 CF differentially methylated genes and their 24 expression-associated
genes (total of 51 genes) leading to 32 interactions (Figure 3.3B). Out of those
32 interactions, 7 had a positive correlation coefficient beta and 27 a negative
one, suggesting suppression of expression associated with hypermethylation or
gene sur-expression associated with hypomethylation.
3.4 Discussion
In this study, we demonstrated that methylation of circulating monocytes is in-
volved in the pathogenesis of acute CF. The strength of our study relies on the
fact that we used only one cell type from PBMCs. Several reports have already
indicated that methylation changes could be cellspecific, and that several vari-
ations between cell types exist within the same individual [248]. Miao et al
[152] demonstrated that monocytes and lymphocytes have distinct epigenomes
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Figure 3.3: Association between methylation and expression in Charcot
foot. A. Schematic representation of CIS and TRANS associ-
ation between methylated and expressed gene. B. Minimum
network of protein-protein interaction using the 27 CF dif-
ferentially methylated genes and their 24 expression associ-
ated genes (total of 51 genes) leading to 32 interactions using
STRING.
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whereas patterns within a specific cell type are remarkably similar despite age
or gender. It might be therefore inappropriate to assess disease-specific methy-
lation changes using PBMCs as a surrogate endpoint. While several reports
linked methylation changes to diabetes and its complications, most of them re-
ported differential gene methylation in PBMCs and only a few assessed cell- or
tissuespecific methylation changes in diabetes [174]. In pancreatic islets from
T2D patients, Volkmar et al [229] identified 276 CpG loci affiliated to promoters
of 254 genes differentially methylated comparing to non-diabetic islets. Nillsson
et al [170] identified over 250 differentially methylated CpG loci in liver tissues
of obese T2D patients as compared to non-diabetic individuals. In our study,
we showed that the analysis of circulating monocytes whole-methylome was
not able to differentiate between the groups of D and DN. CF is a neuropathic
osteoarthropathy [198], and the fact that monocyte WM couldnt discriminate D
and DN demonstrates that methylation differences that we uncovered in this
study are specific to CF.
We identified several genes that are differentially methylated in circulating
monocytes of patients with CF. Furthermore, most of those genes were involved
in the migration process of monocytes and their differentiation into osteoclasts.
The top hit genes were HMGA1 and MAPK11, both hypermethylated. The im-
portant role of P38B (MAPK11) in osteolytic bone destruction has been demon-
strated in the context of breast cancer [79]. Upregulation of MCP1 expression
by MAPK11 leads to the enhanced osteoclast differentiation and bone resorp-
tion. MPAK11 has also been shown to be a regulator of TNF gene expression in
mononuclear phagocytes [139]. HMGA1 is a downstream nuclear target of the
insulin receptor signaling pathway [24]. HMGA1 is a master regulator of tumor
progression by driving inflammatory pathway and cell cycle progression genes
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during tumorigenesis [202].
To strengthen our methylation data, we performed a transcriptomic study
in order to link methylation to gene expression. We demonstrated that only
PPP2R5D was significantly methylated and expressed (cis-association) in CF
patients. The product of this gene belongs to the phosphatase-2A regulatory
subunit B family that is known to be implicated in the negative control of cell
growth and division. In our study, PPP2R5D was hypermethylated and over-
expressed in monocytes of patients with CF, suggesting a decrease of their cell
growth. Interestingly, monocytes have to decrease their division in order to dif-
ferentiate into osteoclasts [219].
The study of trans-association revealed 27 CF-differentially methylated
genes having an effect on 24 expression-associated genes. Among them, some
play an important role in the length of long bones (POC1A) [199] or mono-
cyte trafficking (FOSB) [118]; others are related to glycemic traits in type 1 dia-
betes and T2D [70, 186], insulin resistance (EPHB2) [114] and Golgi trafficking
(ARL5B) [90]. We believe that POC1A and FOSB need to be more investigated
in the context of CF disease. In fact, both are involved in bone-related disorders
such as short stature, onychodysplasia, bone loss or osteosarcoma, rendering
them potential candidate for further functional validation studies in CF disease.
To our knowledge, we are the first to report differential methylation changes
in diabetes and related complications using the ERRBS. Reduced representation
bisulfite sequencing (RRBS), and related methods such as ERRBS, are sequenc-
ing methods that enrich for CpG-rich parts of the genome, which enables se-
quencing of genomic regions where 5-methylcytosine modifications can alter
gene expression via binding to gene promoters and bodies [64, 4, 76]. The ad-
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vantage of this method over whole genome bisulfite sequencing (WGBS) is in-
creased coverage depth and hence higher confidence variant calling for a fixed
volume of sequencing reads. With respect to arraybased epigenome genotyp-
ing platforms such as the HELP array, ERRBS provides higher sensitivity for
rare and population-specific variants [64, 76, 115].
Implications of epigenetics generally, and gene methylation in particular, are
being increasingly used in clinical settings. While drugs that modulate DNA
methylation of cancer cells are already used in oncology treatment [107], the
pharmaco-epigenetic therapy in T2D and cardiovascular disease is currently
limited to experimental studies. For example, inhibition of the methyltrans-
ferase SETD7 that is required for DNA methylation in macrophages resulted in
a decrease in reactive oxygen species and up-regulation of anti-oxydant genes
[78]. Similarly, in an experimental model of db/db mice with diabetic nephropa-
thy, the angiotensin receptor blocker losartan reverses back the methylation of
the histone H3K9 that is observed in mesangial cells under hyperglycemia.
We acknowledge the presence of few limitations in our study. First, our sam-
ple size is relatively small; thus, a higher number of study participants might
have enabled us to detect more methylation calls. Additionally, we used cir-
culating monocytes as surrogate markers for CF knowing that the disease is
only limited to the foot. Despite the presence of those limitations, we were able
to conduct a comprehensive analysis of circulating monocytes methylome in
patients with acute diabetic CF and we demonstrated the presence of differen-
tially methylated genes involved in migration, differentiation and formation of
osteoclasts from circulating monocytes. Moreover, we were able to associate
the difference in methylation with gene expression. Further studies are needed
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to determine the timing of changes in methylation/expression, whether they
precede evidence of acute CF disease or if they could be a downstream effect.
Additionally, it would be important to assess whether the differential methyla-
tion in the acute stage will be present or not in chronic CF disease, and if those
changes are reversible in patients who recover. Nevertheless, our findings could
be used to elucidate the cause of CF, with the ultimate goal of finding means to
modulate or prevent it. Finally, similar methodology could be used to evaluate
the methylome of circulating monocytes in patients with conditions of increased
bone resorption.
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APPENDIX A
CHAPTER 1 OF APPENDIX
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Figure A.1: Joint Methylation & Expression Analysis Pipeline Visualiza-
tion of the pipeline which takes enhanced reduced representa-
tion bisulfite sequencing (ERRBS) CpG methylation data and
integrates it with RNA-Seq gene expression data to produce
data-driven candidate regulatory genes and sites
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APPENDIX B
CHAPTER 3 OF APPENDIX
Figure B.1: Gating strategy for monocyte sorting. A. Monocyte popula-
tions were gated (red population) using SSC/FSC. B-C Us-
ing FSC-W/FSC-h (B) and SSC-W/SSC-H (C), the doublets
were excluded and only the living cells (blue population) were
kept. D. Auto-fluorescent cells were excluded using Pacific-
Blue channel. E. Final monocyte population was gated (orange
population) as CD14(APC)+CD16(PE)+/-.
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Figure B.2: A. Histogram of log10(coverage) at all CpG sites. The blue his-
togram represents the mean of all values in that bin over all
samples. Each black line represents the counts from 1 of the
54 individual samples. B. Histogram of methylation -values at
all CpG sites. The blue histogram represents the mean of all
values in that bin over all samples. Each black line represents
the counts from 1 of the 54 individual samples. C-D. The first
two principal components of autosomal gene methylation for
both (C) the CpG site and (D) gene-mapped analyses, as calcu-
lated by singular value decomposition. Samples are colored by
batch: pink samples were collected in June 2014, orange sam-
ples were collected in February 2015, and gray samples were
collected in March 2015.
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Figure B.3: Differential Methylation for all two-way comparisons of the
three groups using the CpG site approach. First row (A, B,
C): whole-methylome signal as captured by the first three prin-
cipal components (horizontal axes) of the displayed subset of
patients. Violin plots representing the distribution of a partic-
ular patient group along a principal component are adjacent
to their corresponding group. Second row (D, E, F): chromo-
somal distribution of gene methylation differences. For each
gene, the significance is displayed on the y-axis as the log10
of the p-value. The results are ordered along the x-axis by
chromosome, with each bar representing a different chromo-
some. Bonferroni and Benjamini-Hochberg p-value thresholds
are displayed as blue and yellow (dashed) lines, respectively.
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Figure B.4: Differential Methylation for all two-way comparisons of the
three groups using the gene-mapped approach. First row (A,
B, C): whole-methylome signal as captured by the first three
principal components (horizontal axes) of the displayed subset
of patients. Violin plots representing the distribution of a par-
ticular patient group along a principal component are adjacent
to their corresponding group. Second row (D, E, F): chromo-
somal distribution of gene methylation differences. For each
gene, the significance is displayed on the y-axis as the log10
of the p-value. The results are ordered along the x-axis by
chromosome, with each bar representing a different chromo-
some. Bonferroni and Benjamini-Hochberg p-value thresholds
are displayed as blue and yellow (dashed) lines, respectively.
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Figure B.5: Quantile-quantile plots for all two-way comparisons of the
three groups using both CpG site (A, B, C, D) and gene-
mapped (E, F, G, H) differential methylation in patients with
diabetes and CF compared to patients with diabetes but no
CF. Bonferroni and Benjamini-Hochberg p-value thresholds
are displayed as blue and yellow (dashed) lines, respectively.
Differential methylation on permuted data was calculated 10
times for each QQ plot, resulting in 10 sets of null p-values
that are plotted in cyan alongside the non-permuted p-values.
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